0001759186 false 0001759186 2023-06-09 2023-06-09 0001759186 us-gaap:CommonStockMember 2023-06-09 2023-06-09 0001759186 us-gaap:WarrantMember 2023-06-09 2023-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): June 9, 2023

_____________________

 

COEPTIS THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-39669 98-1465952

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

     

105 Bradford Rd, Suite 420

Wexford, Pennsylvania

   15090
(Address of principal executive offices)   (Zip Code)

 

724-934-6467

(Registrant’s telephone number, including area code)

 

____________________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

  

COEP

 		  

Nasdaq Global Market

Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share

  

COEPW

  

Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company     ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

 

 

   
 

 

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On June 8, 2023, the Company received a letter (the “Nasdaq Approval Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that its application to list its common stock and warrants on The Nasdaq Capital Market has been approved, and that the Company’s securities will be transferred from The Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on Tuesday, June 13, 2023.

 

The Nasdaq Approval Letter also confirms that effective simultaneously with the transfer to The Nasdaq Capital Market the previously announced deficiency (announced in the Company’s Current Report on Form 8-K that was filed with the Securities and Exchange Commission on December 29, 2022) will be deemed closed.

 

Item 8.01Other Events

 

On June 9, 2023, the Company issued a press release announcing the transfer of the listing of its securities to The Nasdaq Capital Market, effective as of the opening of business on June 13, 2023. A copy of the press release is included with the Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description

 

99.1

Press Release, dated June 9, 2023

104 Cover Page Interactive Data File (formatted in iXBRL)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Coeptis Therapeutics Holdings, Inc.
     
Date: June 9, 2023 By: /s/ David Mehalick
   

David Mehalick

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Bull Horn (NASDAQ:BHSEU)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Bull Horn Charts.
Bull Horn (NASDAQ:BHSEU)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Bull Horn Charts.